PPT-Chronic Kidney Disease and Cardiovascular Risk

Heather Mascio DO Introduction Chronic Kidney Disease CKD affects around 14 people in the United States Individuals with CKD are 10 times more likely to die of CV disease than the general population and dialysis dependent individuals are at even higher risk around 50 of them will die of CV causes. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Epidemiology. CKD affects about 26 million people in the US. Approximately 19 million adults are in the early stages of the disease . On the rise do to increasing prevalence of diabetes and hypertension. Chronic Kidney Disease: Detection and Management in Primary Care Julia Scialla, MD, MHS, FASN Associate Professor of Medicine and Public Health Sciences University of Virginia Adjunct Associate Professor of Medicine Dr. T. A. L. . Dlamini. Specialist Physician and . Nephrologist. Talk overview . Kidney function. Assessing kidney function. Chronic kidney disease (CKD). Benefits of early detection . Conclusion and take home message . Namita Singh, MD, FASN. Year 2021. DISCLOSURES. I have no financial relationships with commercial interests to disclose.. This presentation does not include discussion of off-label or investigational use. . Chronic . c. are . Training . For . district . hospital . Nurses . in . Rwanda . 2013. Session 1: Defining chronic kidney disease. By the end of this Session, participants will be able to:. Screen for chronic kidney disease. . Structural . or functional abnormalities of the kidneys for . >. 3 months. . from early to late-stage disease, . Chronic Kidney Disease. as . manifested by either:. 1. Kidney . damage, with or without decreased GFR, as . In CKD and HD patients dysfunction of . immu. ne . sy. stem . a. lterations. . belonge. to . . involv. ing. . i. nnate. and . a. daptive. . i. mmunity. in T and B lymphocytes (. Reduced . T regulatory cells and memory cells and increased innate cells). . Featured Clinical Research – Late Breaking Clinical Trials . Residual Inflammatory Risk and Residual Cholesterol Risk Among Statin Treated Atherosclerosis Patients With and Without Chronic Kidney Disease:. Quality Department Guidelines for Clinical Care Ambulatory Chronic Kidney Disease Guideline Team Team Leader Jennifer Reilly Lukela, MD General MedicineTeam MembersR. Van Harrison, PhDMedical Educati ADAPTED FROM:. . The 2023 Scientific Statement From the AHA:. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM). A 2023 Presidential Advisory From the AHA. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM). A systemic disorder characterized by pathophysiologic interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multi-organ dysfunction and a high rate of adverse cardiovascular outcomes.. A Scientific Statement From the AHA. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM). A systemic disorder characterized by pathophysiologic interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multi-organ dysfunction and a high rate of adverse cardiovascular outcomes.. 2017 . Annual Data Report. Volume 1: Chronic Kidney Disease. 2. vol. 1 Figure 4.1 Prevalence of common cardiovascular diseases in patients with or without CKD, 2015 . Data Source: Special analyses, Medicare 5% sample. Abbreviations: AF, atrial fibrillation; AMI, acute myocardial infarction; CAD, coronary artery disease; CKD, chronic kidney disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; CVD, cardiovascular disease; HF, heart failure; PAD, peripheral arterial disease; SCA/VA, sudden cardiac arrest and ventricular arrhythmias; VHD, .